The latest NCCN clinical practice guidelines for colon cancer state that panitumumab or cetuximab should be used as a first-line treatment for only KRAS wild-type LCC among metastatic CRCs.8,28 According to the results of the present study, the biological function and prognostic value of HOXB13 might apply to only RCC. This evidence concerns the gene KRAS and colonic neoplasm.